7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects | ACS Central Science
κ-opioid receptor - Wikipedia
Scientists Just Solved a Major Piece of the Opioid Puzzle | WIRED
Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions | Scientific Reports
Evaluating kratom alkaloids using PHASE | PLOS ONE
Site selective C–H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy | Nature Communications
G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder - Gutridge - 2020 - British Journal of Pharmacology - Wiley Online Library
Kratom - Proteopedia, life in 3D
Majumdar Lab - Research Projects
The effects of kratom on restraint–stress-induced analgesia and its mechanisms of action - ScienceDirect
Neurobiology of Kratom and its main alkaloid mitragynine
Kratom (Mitragyna speciosa) drug profile | www.emcdda.europa.eu
Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom | ACS Chemical Neuroscience
Evaluating kratom alkaloids using PHASE | PLOS ONE
Opioid-based plant might not be best solution for those seeking to curb habitual alcohol use - Purdue University News
Kratom | National Institute on Drug Abuse (NIDA)
Frontiers | Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder
Opioid receptors: drivers to addiction? | Nature Reviews Neuroscience
Simulated Side Effects: FDA Uses Novel Computer Model to Guide Kratom Policy | Bill of Health
Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. | Semantic Scholar
Kappa Opioid Receptor Structure Revealed, A Potential Milestone in Medication Development | National Institute on Drug Abuse (NIDA)
Molecules | Free Full-Text | Biased Opioid Ligands
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
